Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line
| Image |  |
|---|---|
| Description | scientific article published on 01 October 2018 |
| Author/s |
author: Nicoletta Colombo |
| Publication date | October 1, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |